Hanns-Ulrich Marschall
Hanns-Ulrich Marschall
Sahlgrenska Academy, Institute of Medicine, Department of Molecular and Clinical Medicine
Verifierad e-postadress på gu.se - Startsida
TitelCiteras avÅr
Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease
O Ringdén, M Uzunel, I Rasmusson, M Remberger, B Sundberg, ...
Transplantation 81 (10), 1390-1397, 2006
12372006
EASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association For The Study Of The Liver
Journal of hepatology 51 (2), 237-267, 2009
11122009
Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist
SI Sayin, A Wahlström, J Felin, S Jäntti, HU Marschall, K Bamberg, ...
Cell metabolism 17 (2), 225-235, 2013
8712013
Intrahepatic cholestasis of pregnancy: relationships between bile acid levels and fetal complication rates
A Glantz, HU Marschall, LÅ Mattsson
Hepatology 40 (2), 467-474, 2004
7642004
Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease
S Mudaliar, RR Henry, AJ Sanyal, L Morrow, HU Marschall, M Kipnes, ...
Gastroenterology 145 (3), 574-582. e1, 2013
5432013
Intrahepatic cholestasis of pregnancy: molecular pathogenesis, diagnosis and management
F Lammert, HU Marschall, A Glantz, S Matern
Journal of hepatology 33 (6), 1012-1021, 2000
5292000
Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism
A Wahlström, SI Sayin, HU Marschall, F Bäckhed
Cell metabolism 24 (1), 41-50, 2016
3882016
Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice
P Fickert, A Fuchsbichler, M Wagner, G Zollner, A Kaser, H Tilg, R Krause, ...
Gastroenterology 127 (1), 261-274, 2004
3812004
A placebo-controlled trial of obeticholic acid in primary biliary cholangitis
F Nevens, P Andreone, G Mazzella, SI Strasser, C Bowlus, P Invernizzi, ...
New England Journal of Medicine 375 (7), 631-643, 2016
3662016
Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid
GM Hirschfield, A Mason, V Luketic, K Lindor, SC Gordon, M Mayo, ...
Gastroenterology 148 (4), 751-761. e8, 2015
3462015
High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study
R Olsson, KM Boberg, OS de Muckadell, S Lindgren, R Hultcrantz, ...
Gastroenterology 129 (5), 1464-1472, 2005
3352005
Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations
G Zollner, HU Marschall, M Wagner, M Trauner
Molecular pharmaceutics 3 (3), 231-251, 2006
3182006
Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid
A Glantz, HU Marschall, F Lammert, LÅ Mattsson
Hepatology 42 (6), 1399-1405, 2005
3042005
CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice
M Wagner, E Halilbasic, HU Marschall, G Zollner, P Fickert, C Langner, ...
Hepatology 42 (2), 420-430, 2005
2912005
Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis
G Zollner, P Fickert, D Silbert, A Fuchsbichler, HU Marschall, K Zatloukal, ...
Journal of hepatology 38 (6), 717-727, 2003
2802003
Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans
HU Marschall, M Wagner, G Zollner, P Fickert, U Diczfalusy, J Gumhold, ...
Gastroenterology 129 (2), 476-485, 2005
2642005
Ursodeoxycholic acid aggravates bile infarcts in bile duct–ligated and Mdr2 knockout mice via disruption of cholangioles
P Fickert, G Zollner, A Fuchsbichler, C Stumptner, AH Weiglein, ...
Gastroenterology 123 (4), 1238-1251, 2002
2592002
Genetic and environmental influences on symptomatic gallstone disease: a Swedish study of 43,141 twin pairs
D Katsika, A Grjibovski, C Einarsson, F Lammert, P Lichtenstein, ...
Hepatology 41 (5), 1138-1143, 2005
2542005
24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice
P Fickert, M Wagner, HU Marschall, A Fuchsbichler, G Zollner, ...
Gastroenterology 130 (2), 465-481, 2006
2532006
Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis
JZ Liu, JR Hov, T Folseraas, E Ellinghaus, SM Rushbrook, NT Doncheva, ...
Nature genetics 45 (6), 670, 2013
2442013
Systemet kan inte utföra åtgärden just nu. Försök igen senare.
Artiklar 1–20